Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKSNASDAQ:BCRXNASDAQ:INVANASDAQ:LGND On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$29.83-3.1%$29.66$22.90▼$36.45$4.92B0.471.73 million shs2.21 million shsBCRXBioCryst Pharmaceuticals$10.37-0.3%$9.37$5.92▼$11.31$2.17B1.113.04 million shs2.66 million shsINVAInnoviva$21.69+1.4%$18.99$15.70▼$21.98$1.36B0.37678,053 shs1.42 million shsLGNDLigand Pharmaceuticals$112.50-1.7%$105.48$77.53▼$129.90$2.17B0.83116,608 shs83,330 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes0.00%-5.93%-4.42%-12.34%+20.09%BCRXBioCryst Pharmaceuticals0.00%-6.07%+1.57%+34.68%+64.60%INVAInnoviva0.00%+0.51%+18.33%+24.73%+36.42%LGNDLigand Pharmaceuticals0.00%+6.14%+8.73%+5.94%+40.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALKSAlkermes4.6857 of 5 stars4.41.00.04.22.82.51.9BCRXBioCryst Pharmaceuticals4.3452 of 5 stars4.41.00.04.22.91.70.6INVAInnoviva4.0041 of 5 stars3.50.00.04.22.01.71.9LGNDLigand Pharmaceuticals4.3824 of 5 stars3.50.00.04.42.53.31.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 2.77Moderate Buy$38.8530.23% UpsideBCRXBioCryst Pharmaceuticals 2.89Moderate Buy$16.5659.65% UpsideINVAInnoviva 3.00Buy$55.00153.57% UpsideLGNDLigand Pharmaceuticals 3.00Buy$146.1429.90% UpsideCurrent Analyst Ratings BreakdownLatest INVA, ALKS, BCRX, and LGND Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025ALKSAlkermesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral ➝ Buy$45.005/13/2025ALKSAlkermesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025LGNDLigand PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$142.00 ➝ $145.005/7/2025BCRXBioCryst PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $11.005/6/2025BCRXBioCryst PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.00 ➝ $13.005/6/2025BCRXBioCryst PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$10.00 ➝ $13.005/6/2025BCRXBioCryst PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $17.005/6/2025BCRXBioCryst PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/2/2025ALKSAlkermesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/2/2025ALKSAlkermesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$39.00 ➝ $40.005/2/2025ALKSAlkermesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$38.00 ➝ $41.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.51B3.25$2.24 per share13.32$9.05 per share3.30BCRXBioCryst Pharmaceuticals$503.49M4.31N/AN/A($2.22) per share-4.67INVAInnoviva$369.84M3.68$4.20 per share5.17$10.66 per share2.03LGNDLigand Pharmaceuticals$181.49M11.96$4.61 per share24.39$40.39 per share2.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$367.07M$2.0913.7521.772.2023.57%30.80%19.09%7/23/2025 (Estimated)BCRXBioCryst Pharmaceuticals-$226.54M-$0.26N/AN/AN/A-30.01%N/A-24.06%8/4/2025 (Estimated)INVAInnoviva$179.72M-$1.0131.4413.99N/A18.31%20.84%11.38%7/29/2025 (Estimated)LGNDLigand Pharmaceuticals$52.15M-$7.1244.8230.32N/A29.68%4.95%4.39%8/5/2025 (Estimated)Latest INVA, ALKS, BCRX, and LGND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025LGNDLigand Pharmaceuticals$1.23$1.33+$0.10-$2.21$37.84 million$45.33 million5/7/2025Q1 2025INVAInnovivaN/A$0.25N/A-$0.74N/A$88.63 million5/1/2025Q1 2025ALKSAlkermes$0.32$0.13-$0.19$0.13$307.53 million$306.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/ABCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermesN/A3.042.65BCRXBioCryst PharmaceuticalsN/A2.782.73INVAInnoviva0.381.791.64LGNDLigand PharmaceuticalsN/A12.4911.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%BCRXBioCryst Pharmaceuticals85.88%INVAInnoviva99.12%LGNDLigand Pharmaceuticals91.28%Insider OwnershipCompanyInsider OwnershipALKSAlkermes4.40%BCRXBioCryst Pharmaceuticals4.80%INVAInnoviva2.25%LGNDLigand Pharmaceuticals7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes2,280164.90 million154.66 millionOptionableBCRXBioCryst Pharmaceuticals530209.25 million197.19 millionOptionableINVAInnoviva10062.78 million61.54 millionOptionableLGNDLigand Pharmaceuticals8019.29 million17.78 millionOptionableINVA, ALKS, BCRX, and LGND HeadlinesRecent News About These CompaniesLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Sells $57,270.00 in StockJune 13 at 8:42 AM | insidertrades.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives $146.14 Consensus Target Price from AnalystsJune 13 at 1:33 AM | americanbankingnews.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Andrew Reardon Sells 500 SharesJune 12 at 9:01 PM | marketbeat.comLGND Makes Bullish Cross Above Critical Moving AverageJune 11, 2025 | nasdaq.comLigand Announces 2025 Investor Day in New York CityJune 11, 2025 | globenewswire.comGAMMA Investing LLC Purchases 61,996 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)June 10, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Consensus Rating of "Buy" from BrokeragesJune 10, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Bought by Congress Asset Management Co.June 7, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Andrew Reardon Sells 1,000 SharesJune 3, 2025 | marketbeat.comAndrew Reardon Sells 1,000 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) StockJune 3, 2025 | insidertrades.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $5.40 Million Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)June 3, 2025 | marketbeat.comSummit Global Investments Acquires 6,407 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)June 1, 2025 | marketbeat.comKings Path Partners LLC Reduces Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)May 31, 2025 | marketbeat.comSquarepoint Ops LLC Purchases Shares of 16,799 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)May 31, 2025 | marketbeat.comBank of America Corp DE Purchases 2,533 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)May 25, 2025 | marketbeat.comCastleark Management LLC Cuts Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)May 23, 2025 | marketbeat.comGraham Capital Management L.P. Makes New Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)May 18, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of "Buy" by BrokeragesMay 18, 2025 | marketbeat.comDeutsche Bank AG Purchases 15,160 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)May 16, 2025 | marketbeat.comJanus Henderson Group PLC Acquires 5,929 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)May 15, 2025 | marketbeat.comLigand to Ring the Nasdaq Opening Bell on May 19, 2025May 14, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINVA, ALKS, BCRX, and LGND Company DescriptionsAlkermes NASDAQ:ALKS$29.83 -0.95 (-3.09%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$29.81 -0.02 (-0.07%) As of 06/13/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.BioCryst Pharmaceuticals NASDAQ:BCRX$10.37 -0.03 (-0.29%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$10.40 +0.03 (+0.29%) As of 06/13/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Innoviva NASDAQ:INVA$21.69 +0.29 (+1.36%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$21.68 -0.02 (-0.07%) As of 06/13/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Ligand Pharmaceuticals NASDAQ:LGND$112.50 -1.95 (-1.70%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$112.52 +0.02 (+0.02%) As of 06/13/2025 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
